Fellowship · Houston, TX
Sponsored by University of Texas Health Science Center at Houston
Nerandomilast in Patients with Progressive Pulmonary Fibrosis.
The New England journal of medicine · 2025 · 146 citations · Shervin Assassi
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
Arthritis & rheumatology (Hoboken, N.J.) · 2024 · 174 citations · Shervin Assassi, Zsuzsanna McMahan
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
Arthritis & rheumatology (Hoboken, N.J.) · 2024 · 132 citations · Shervin Assassi, Zsuzsanna McMahan
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.
Nature medicine · 2023 · 334 citations · Yuanteng Li
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
Arthritis care & research · 2024 · 111 citations ·
Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclature.
Annals of the rheumatic diseases · 2024 · 101 citations · John Reveille
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Respiratory research · 2023 · 105 citations · Maureen Mayes
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
The Lancet. Respiratory medicine · 2021 · 175 citations · Shervin Assassi, Maureen Mayes